Psychosocial and Medical Aspects of Systematic Lupus Erythematosus (SLE)

Psychosocial and Medical Aspects of Systematic Lupus Erythematosus (SLE) - HRQoL and chimerism in SLE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32104

Enrollment

Registered

2008-04-17

Start date

2008-02-04

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lupus SLE

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: A diagnosis of proliferative lupus nephritis and a received treatment according to either the NIH or the Euro-Lupus protocol.

Exclusion criteria

Exclusion criteria: Patients with proliferative lupus-nephritis who were not treated according to the NIH- or Euro-Lupus protocol and patients with a diagnosis of non-proliferative lupus nephritis are excluded from the study.

Design outcomes

Primary

Measure	Time frame
The most important study parameter is the difference in quality of life between patients that received the NIH treatment and patients that were treated according to the Euro-Lupus schema. Analysis of the drawings will encover which parameters are of meaning, thus in which the two groups differ from each other. In addition, the relation between the level of HRQol and illness perceptions as well as disease activity parameters will be investigated.	—

Measure

Time frame

The most important study parameter is the difference in quality of life between patients that received the NIH treatment and patients that were treated according to the Euro-Lupus schema. Analysis of the drawings will encover which parameters are of meaning, thus in which the two groups differ from each other. In addition, the relation between the level of HRQol and illness perceptions as well as disease activity parameters will be investigated.

—

Secondary

Measure	Time frame
The presence of chimeric cells in blood of the female participants.	—

Countries

Netherlands

Outcome results